Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study - Takeaways - MDSpire

Utilization and Adoption of Biologic Treatments in Pediatric Immune-Mediated Inflammatory Disorders: A Population-Based Analysis from Australia

  • By

  • Jun Ni Ho

  • Jodie Hillen

  • Natasha Nassar

  • Helga Zoega

  • Timothy Beukelman

  • Nicole Pratt

  • Benjamin Daniels

  • July 1, 2026

Share

  • 1

    Pediatric immune-mediated inflammatory diseases (IMIDs) are characterized by chronic systemic inflammation affecting children.

  • 2

    The number of biologic medicines for treating pediatric IMIDs has significantly increased over the past two decades.

  • 3

    Ten biologic medicines are currently approved by the Therapeutic Goods Administration for pediatric IMIDs in Australia.

  • 4

    Safety data for biologic medicines in children is often lacking due to the exclusion of pediatric populations in clinical trials.

  • 5

    This study aims to quantify the use of biologic medicines and characterize the pediatric population initiating these treatments in Australia.

Original Source(s)

Uptake and Use of Biologic Therapies in Paediatric Immune-Mediated Inflammatory Diseases: An Australian Population-Based Study

  • by Jun Ni Ho, Jodie Hillen, Natasha Nassar, Helga Zoega, Timothy Beukelman, Nicole Pratt, Benjamin Daniels

  • July 1, 2026

Related Content

Immunopathogenesis of severe pneumonia in children with emphasis on CD4+ T cells, Tim-3 and cytokine-mediated immune dysregulation

Non-metastatic pediatric head and neck rhabdomyosarcoma: a 24-year retrospective experience from Jordan

Clinical characteristics of pediatric tumor-induced osteomalacia: a systematic review and individual patient data analysis